Neoadjuvant T-VEC in High Risk Early Melanoma

Inclusion Criteria 1. Ability to understand and willingness to sign an informed consent form. 2. Ability to adhere to the study visit schedule and other protocol requirements. 3. Men and women ≥18 years of age. 4. ECOG performance status score of 0-1 (Appendix 13.1) / Karnofsky Performance Status (KPS) performance status of 60% or greater. 5. Life expectancy ≥ 3 months. 6. Hematology parameters defined by: 1. Absolute neutrophil count (ANC) ≥ 1.5 × 109/L, 2. Platelet count ≥ 75 × 109/L, and 3. Hemoglobin ≥ 8 g/dL (may have been transfused) 7. Blood chemistry levels defined by: 1. Total bilirubin level ≤ 1.5 × the upper limit of normal (ULN) range 2. AST and ALT levels ≤ 2.5 × ULN or AST and ALT levels ≤ 5 x ULN (for subjects with documented metastatic disease to the liver). 3. INR and aPTT ≤1.5 x ULN (for patients on anticoagulation they must be receiving a stable dose for at least 1 week prior to first treatment) 4. Creatinine clearance ≥ 30 mL/min by Cockcroft-Gault formula. 8. Subjects with active hepatitis B virus (Hep B) and with untreated hepatitis C virus (HCV) are allowed. 9. Willingness to undergo mandatory pre-treatment biopsy (unless there is adequate archival tumor specimen available) and mandatory on-treatment biopsy. 10. Female subjects who are of non-reproductive potential (i.e., post-menopausal by history - no menses for ≥1 year; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy). Or, female subjects of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to the first study drug administration. 11. Male and female subjects who agree to use highly effective method of birth control (e.g., implants, injectables, birth control pills with two hormones, intrauterine devices \[IUDs\], complete abstinence or sterilized partner, and female sterilization) and a barrier method (e.g., condoms, vaginal ring, sponge, etc.) during the period of therapy and for 90 days after the last dose of study drug. 12. Biopsy-proven resectable primary cutaneous melanoma \> 2.0mm in depth with residual tumor or local, in-transit, or dermal oligometastatic resectable recurrence in a treatment- naïve patient not otherwise eligible for systemic therapy 13. Residual pigmented cutaneous lesion accessible to intralesional injection Exclusion Criteria 1. Pregnant or lactating women. 2. Any psychiatric condition that would prohibit the understanding or rendering of informed consent. 3. Any significant medical condition including additional malignancies, laboratory abnormalities, or psychiatric illness that would prevent the subject from participating and adhering to study related procedures. 4. Uncontrolled concomitant disease that in the opinion of the investigator would interfere with the patient's safety or compliance on trial. 5. Severe infection that in the opinion of the investigator would interfere with patient safety or compliance on trial within 4 weeks prior to enrollment. 6. Melanoma \>/= 2.0mm in depth without residual disease following biopsy 7. Previous exposure to talimogene laherparepvec or systemic therapies 8. Concurrent cancer or treatment for a concurrent cancer, except treated non-melanoma skin cancer 9. Regional or systemic metastases 10. History of evidence of symptomatic autoimmune disease requires systemic treatment (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. 11. Immunosuppressed state, including the following: * Primary immunodeficiency state such as Severe Combined Immunodeficiency Disease, concurrent opportunistic infection, receiving systemic immunosuppressive therapy (\> 2 weeks) including oral steroid doses \> 10 mg/day of prednisone or equivalent within 7 days prior to enrollment. * Prior immunosuppressive, chemotherapy, radiotherapy (in which the field encompassed a planned injection site), biological cancer therapy, or major surgery within 28 days prior to enrollment or has not recovered to CTCAE grade 1 or better from adverse event due to cancer therapy administered more than 28 days prior to enrollment. * Active human immunodeficiency virus (HIV) infection 12. Active herpetic skin lesions or prior complication of herpes simplex virus-1 infection (e.g., herpetic keratitis or encephalitis). 13. Current enrollment in another clinical trial 14. Patients who are know to be sensitive to any of the products or components of T-VEC 15. Requires intermittent or chronic systemic (intravenous or oral) treatment with an antiherpetic drug (e.g., acyclovir), other than intermittent topical use. 16. Previous treatment with talimogene laherparepvec or any other oncolytic virus. 17. Prior therapy with tumor vaccine or received live vaccine within 28 days prior to enrollment. 18. Adjuvant hormonal therapy is allowed if appropriate for planned study. 19. Prior radiotherapy in which the field does not overlap the injection sites or non- immunosuppressive targeted therapy within 14 days prior to enrollment or has not recovered to CTCAE grade 1 or better from adverse event due to cancer therapy administered more than 14 days prior to enrollment 20. History of other malignancy within the past 5 years with the following exceptions: * Adequately treated non melanoma skin cancer without evidence of disease at the time of enrollment * Adequately treated cervical carcinoma in situ without evidence of disease at the time of enrollment * Adequately treated breast ductal carcinoma in situ without evidence of disease at the time of enrollment * Prostatic intraepithelial neoplasia without evidence of prostate cancer at the time of enrollment. 21. Subjects who are unwilling to minimize exposure with his/her blood or other body fluids to individuals who are at higher risks for HSV-1 induced complications such as immunosuppressed individuals, individuals known to have HIV infection, pregnant women, or infants under the age of 3 months, during talimogene laherparepvec treatment and through 30 days after the last dose